McDermott Advises on $170M Cross-Border Deal
NEW YORK — A cross-disciplinary legal team from throughout McDermott Will & Emery’s international offices, is acting as outside counsel to Centerpulse Ltd. in the $170 million sale of its Vascutek vascular grafts business to Terumo Corporation, a Japanese medical device company.
This sale, the second step in Centerpulse's plan to divest its cardiovascular interests, follows after Centerpulse’s September announcement regarding the sale of IntraTherapeutics for $95 million. McDermott is also advising Centerpulse on the sale of IntraTherapeutics to Microvena Corporation and the pending sale of its remaining cardiovascular interests.
Centerpulse, Ltd., headquartered in Switzerland, and its subsidiaries develop, produce and distribute medical implants and biological materials for cardiovascular and orthopedic markets worldwide. Its products include artificial joints, dental implants, spinal implants and instrumentation, trauma products, heart valves, synthetic blood vessels and stents for vascular and non-vascular obstructions. For additional information, visit www.centerpulse.com.
Terumo Corporation, based in Tokyo, manufactures and distributes a range of medical products, including cardiovascular technologies and implants, which are sold worldwide.
